| Dr Mark Allen Esche, MD | |
|
4101 Parkstone Heights Dr Ste 360, Austin, TX 78746-7482 | |
| (512) 637-9551 | |
| (512) 340-0096 |
| Full Name | Dr Mark Allen Esche |
|---|---|
| Gender | Male |
| Speciality | Psychiatry |
| Experience | 27 Years |
| Location | 4101 Parkstone Heights Dr Ste 360, Austin, Texas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1174622740 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084P0800X | Psychiatry & Neurology - Psychiatry | L3636 (Texas) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Austin Psychiatric Alliance, Pllc | 8921153909 | 2 |
News Archive
At the present, no cure exists for Parkinson's disease, although symptomatic intervention, including treatment with dopamine agonists, can alleviate patients' motor impairment. Parkinson's is the second most common neurodegenerative disorder, after Alzheimer's disease; it is estimated that 100,000 to 300,000 patients are affected by Parkinson's disease in Germany alone.
Centocor, Inc., announced today that the U.S. Food and Drug Administration (FDA) has accepted its filing of a supplemental Biologics License Application (sBLA) for REMICADE® (infliximab) as first-line therapy, in combination with methotrexate, for the treatment of early rheumatoid arthritis (RA) patients with moderately-to-severely active disease. REMICADE®, in combination with methotrexate, is currently indicated in the U.S. for reducing signs and symptoms, inhibiting the progression of structural damage and improving physical function in patients with moderately-to-severely active RA who have had an inadequate response to methotrexate alone.
Enobia Pharma today announced positive interim data from a clinical study of ENB-0040, a bone targeted enzyme replacement therapy, under investigation for the treatment of hypophosphatasia (HPP). After 12 weeks of treatment with ENB-0040, children with HPP showed marked improvements in bone mineralization and function including increases in strength, endurance and mobility and reduction in pain. These findings were presented by Dr. Michael Whyte at ENDO 2010, the 92nd Annual Meeting of The Endocrine Society.
A team of LSU Health New Orleans pathologists published what is believed to be the first case report on pathologic findings of vasculitis of the small vessels of the heart, which likely represents multisystem inflammatory syndrome.
› Verified 7 days ago
| Entity Name | Austin Psychiatric Alliance, Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1053591339 PECOS PAC ID: 8921153909 Enrollment ID: O20090826000728 |
News Archive
At the present, no cure exists for Parkinson's disease, although symptomatic intervention, including treatment with dopamine agonists, can alleviate patients' motor impairment. Parkinson's is the second most common neurodegenerative disorder, after Alzheimer's disease; it is estimated that 100,000 to 300,000 patients are affected by Parkinson's disease in Germany alone.
Centocor, Inc., announced today that the U.S. Food and Drug Administration (FDA) has accepted its filing of a supplemental Biologics License Application (sBLA) for REMICADE® (infliximab) as first-line therapy, in combination with methotrexate, for the treatment of early rheumatoid arthritis (RA) patients with moderately-to-severely active disease. REMICADE®, in combination with methotrexate, is currently indicated in the U.S. for reducing signs and symptoms, inhibiting the progression of structural damage and improving physical function in patients with moderately-to-severely active RA who have had an inadequate response to methotrexate alone.
Enobia Pharma today announced positive interim data from a clinical study of ENB-0040, a bone targeted enzyme replacement therapy, under investigation for the treatment of hypophosphatasia (HPP). After 12 weeks of treatment with ENB-0040, children with HPP showed marked improvements in bone mineralization and function including increases in strength, endurance and mobility and reduction in pain. These findings were presented by Dr. Michael Whyte at ENDO 2010, the 92nd Annual Meeting of The Endocrine Society.
A team of LSU Health New Orleans pathologists published what is believed to be the first case report on pathologic findings of vasculitis of the small vessels of the heart, which likely represents multisystem inflammatory syndrome.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Mark Allen Esche, MD 4101 Parkstone Heights Dr Ste 360, Austin, TX 78746-7482 Ph: (512) 637-9090 | Dr Mark Allen Esche, MD 4101 Parkstone Heights Dr Ste 360, Austin, TX 78746-7482 Ph: (512) 637-9551 |
News Archive
At the present, no cure exists for Parkinson's disease, although symptomatic intervention, including treatment with dopamine agonists, can alleviate patients' motor impairment. Parkinson's is the second most common neurodegenerative disorder, after Alzheimer's disease; it is estimated that 100,000 to 300,000 patients are affected by Parkinson's disease in Germany alone.
Centocor, Inc., announced today that the U.S. Food and Drug Administration (FDA) has accepted its filing of a supplemental Biologics License Application (sBLA) for REMICADE® (infliximab) as first-line therapy, in combination with methotrexate, for the treatment of early rheumatoid arthritis (RA) patients with moderately-to-severely active disease. REMICADE®, in combination with methotrexate, is currently indicated in the U.S. for reducing signs and symptoms, inhibiting the progression of structural damage and improving physical function in patients with moderately-to-severely active RA who have had an inadequate response to methotrexate alone.
Enobia Pharma today announced positive interim data from a clinical study of ENB-0040, a bone targeted enzyme replacement therapy, under investigation for the treatment of hypophosphatasia (HPP). After 12 weeks of treatment with ENB-0040, children with HPP showed marked improvements in bone mineralization and function including increases in strength, endurance and mobility and reduction in pain. These findings were presented by Dr. Michael Whyte at ENDO 2010, the 92nd Annual Meeting of The Endocrine Society.
A team of LSU Health New Orleans pathologists published what is believed to be the first case report on pathologic findings of vasculitis of the small vessels of the heart, which likely represents multisystem inflammatory syndrome.
› Verified 7 days ago
Dr. Chad Alan Hooten, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 601 E 15th St, Austin, TX 78701 Phone: 512-324-2000 | |
Kristin Yeung Lasseter, MD Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 4022 Menchaca Rd, Austin, TX 78704 Phone: 512-982-4116 Fax: 512-265-9008 | |
Priyanka Gurru, Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 1201 W 38th St, Austin, TX 78705 Phone: 512-495-5555 | |
Kira Allison, DO Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 1500 Red River St, Austin, TX 78701 Phone: 512-495-5555 | |
Robert Feinstein, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 1601 Trinity St, Austin, TX 78712 Phone: 833-882-2737 Fax: 888-698-8329 | |
Ava M. Lee, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 56 East Ave, Austin, TX 78701 Phone: 512-472-4357 Fax: 512-703-1394 | |
Dr. Lindsay Erin Elton, M.D. Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 7940 Shoal Creek Blvd Ste 100, Austin, TX 78757 Phone: 512-494-4000 Fax: 512-494-4024 |